MX2011012015A - Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. - Google Patents
Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.Info
- Publication number
- MX2011012015A MX2011012015A MX2011012015A MX2011012015A MX2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A
- Authority
- MX
- Mexico
- Prior art keywords
- mci
- alzheimer
- disease
- treatment
- nifedipine
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- -1 nitroso nifedipine derivatives Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940034208 thyroxine Drugs 0.000 abstract 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21645209P | 2009-05-15 | 2009-05-15 | |
| US23455109P | 2009-08-17 | 2009-08-17 | |
| PCT/US2010/034721 WO2010132671A1 (en) | 2009-05-15 | 2010-05-13 | Treatment of mci and alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012015A true MX2011012015A (es) | 2012-04-30 |
Family
ID=43069025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012015A MX2011012015A (es) | 2009-05-15 | 2010-05-13 | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100292281A1 (https=) |
| EP (1) | EP2429992A4 (https=) |
| JP (1) | JP2012526844A (https=) |
| AU (1) | AU2010249015A1 (https=) |
| CA (1) | CA2761298A1 (https=) |
| MX (1) | MX2011012015A (https=) |
| WO (1) | WO2010132671A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE024953T2 (en) | 2004-08-23 | 2016-02-29 | Yeda Res & Dev | Peptide inhibitors to mediate stress responses |
| BRPI0616454A2 (pt) | 2005-09-30 | 2011-06-21 | Vitae Pharmaceuticals, Inc. | métodos de tratamento de cáncer |
| EP2715350B1 (en) | 2011-05-23 | 2017-09-27 | Yeda Research and Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| CA2838562A1 (en) * | 2011-08-08 | 2013-02-14 | Eugenia Wang | Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| MX352727B (es) | 2011-12-13 | 2017-12-06 | Dartmouth College | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
| KR20150027800A (ko) * | 2012-06-15 | 2015-03-12 | 고에키 자이단 호징 센탄 이료 신코 자이단 | 경도 인지 장해의 예방 및/또는 치료제 |
| US8901305B2 (en) * | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| WO2017075607A1 (en) | 2015-10-31 | 2017-05-04 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones |
| KR20180121983A (ko) | 2016-03-10 | 2018-11-09 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료 |
| CA3016876C (en) | 2016-03-10 | 2021-12-28 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
| US11517549B2 (en) * | 2017-09-20 | 2022-12-06 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| MX2024006978A (es) | 2021-12-07 | 2024-07-19 | Io Therapeutics Inc | Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2126533A1 (de) * | 1971-05-28 | 1972-12-14 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur Herstellung pharma zeutischer Zubereitungen |
| DE4342196A1 (de) * | 1993-12-10 | 1995-06-14 | Bayer Ag | Neue 4-Phenyl-substituierte 1,4-Dihydropyridine |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP2311806A3 (en) * | 1996-01-29 | 2011-08-10 | The United States of America, Represented by the Secretary, Department of Health and Human Services | Dihydropyridine-, pyridine-, benzopyranone- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists |
| AU2794199A (en) * | 1998-02-26 | 1999-09-15 | Robertas Bunevicius | Thyroid hormone replacement using sustained release triiodothyronine |
| US6558650B1 (en) * | 1998-04-08 | 2003-05-06 | Oregon Health And Science University | Enhancement of cellular gallium uptake |
| CA2525970C (en) * | 2003-05-15 | 2011-03-22 | Roskamp Research, Llc | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| WO2005051389A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceuticals Corporation | Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| WO2006040153A2 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| EP1874311B1 (en) * | 2005-04-15 | 2011-10-05 | Research & Innovation S.p.A. | A method for preventing, delaying or reverting abnormal amyloid deposition |
| WO2006116499A1 (en) * | 2005-04-26 | 2006-11-02 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| JP2007091664A (ja) * | 2005-09-29 | 2007-04-12 | Univ Of Tokushima | 細胞膜保護剤 |
| US20090286879A1 (en) * | 2005-12-02 | 2009-11-19 | Kiyoshi Hashizume | Preventive or Therapeutic Drug for Alzheimer-Type Dementia |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| JP2009073759A (ja) * | 2007-09-20 | 2009-04-09 | Univ Of Tokushima | Ｉｃａｍ−１発現抑制剤 |
-
2010
- 2010-05-13 MX MX2011012015A patent/MX2011012015A/es not_active Application Discontinuation
- 2010-05-13 AU AU2010249015A patent/AU2010249015A1/en not_active Abandoned
- 2010-05-13 EP EP10775535A patent/EP2429992A4/en not_active Withdrawn
- 2010-05-13 JP JP2012511013A patent/JP2012526844A/ja active Pending
- 2010-05-13 CA CA2761298A patent/CA2761298A1/en not_active Abandoned
- 2010-05-13 WO PCT/US2010/034721 patent/WO2010132671A1/en not_active Ceased
- 2010-05-13 US US12/779,345 patent/US20100292281A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010132671A1 (en) | 2010-11-18 |
| US20100292281A1 (en) | 2010-11-18 |
| AU2010249015A1 (en) | 2011-11-24 |
| EP2429992A1 (en) | 2012-03-21 |
| EP2429992A4 (en) | 2012-11-28 |
| CA2761298A1 (en) | 2010-11-18 |
| JP2012526844A (ja) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| MY177001A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| TW200637522A (en) | Skin treatment articles and methods | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| MY172372A (en) | Compositions and methods for lowering triglycerides | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
| MY147247A (en) | Organic compounds and their uses | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| PL1919466T3 (pl) | Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu | |
| EA200701995A1 (ru) | Способы уменьшения кальцификации | |
| TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
| NZ606276A (en) | Fastening Means | |
| UA85471C2 (ru) | Применение оксикодона для лечения висцеральной боли | |
| TW200716088A (en) | Formulations and methods for treating amyloidosis | |
| MX2007005526A (es) | Tratamiento de mastitis con enrofloxacino. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |